JOB 2018-10-15 Employer Aquinnah Pharmaceuticals Contact firstname.lastname@example.org Description Aquinnah Pharmaceuticals is hiring exceptional Ph.D. scientists to expand its exciting new Alzheimer’s disease drug discovery and development programs. The successful ...
COMMENT We noted in a study by Geser et al., 2010, that pathological 43-kDa transactivation response DNA-binding protein (TDP-43) was present to a variable extent in the postmortem brains of 29 percent of longitudinally followed older (>age 65) schizophrenia ...
Kaiser Permanente San Pedro, United States
PAPER Lu X30315450
PAPER Joy T, Rao MS, Madhyastha S
N-Acetyl Cysteine Supplement Minimize Tau Expression and Neuronal Loss in Animal Model of Alzheimer's Disease.Brain Sci. 2018 Oct 11;8(10) PubMed: 30314380
PAPER Olfati N, Shoeibi A, Litvan I30314846
PAPER Shaw CA30315449
PAPER Kang HG, Park HY, Ryu HU, Suk SH30313083
PAPER Massenzio F, Peña-Altamira E, Petralla S, Virgili M, Zuccheri G, Miti A, Polazzi E, Mengoni I, Piffaretti D, Monti B
Microglial overexpression of fALS-linked mutant SOD1 induces SOD1 processing impairment, activation and neurotoxicity and is counteracted by the autophagy inducer trehalose.Biochim Biophys Acta Mol Basis Dis. 2018 Oct 10; PubMed: 30315929
PAPER Wang L30315448
PAPER Kumar V, Wahiduzzaman, Prakash A, Tomar AK, Srivastava A, Kundu B, Lynn AM, Imtaiyaz Hassan M30315897
PAPER Perttila NM, Öhman H, Strandberg TE, Kautiainen H, Raivio M, Laakkonen ML, Savikko N, Tilvis RS, Pitkälä KH
Effect of Exercise on Drug-Related Falls Among Persons with Alzheimer's Disease: A Secondary Analysis of the FINALEX Study.Drugs Aging. 2018 Oct 13; PubMed: 30315403
No filters selected